Abstract:SARS-CoV-2 is spreading around the world for the past year. Enormous efforts have been taken to understand its mechanism of transmission. It is well established now that the receptor-binding domain (RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) as its first step of entry. Being a single-stranded RNA virus, SARS-CoV-2 is evolving rapidly. Recently, several variants such as B.1.1.7, B.1.351, and P.1, with a key mutation N501Y on the RBD, appear to be more infectious to humans. To understand its mechanism, we combined cell surface binding assay, kinetics study, single-molecule technique, and computational method to investigate the interaction between these RBD (mutations) and ACE2. Remarkably, RBD with the N501Y mutation exhibited a considerably stronger interaction characterized from all these methodologies, while the other two mutations from B.1.351 contributed to a less effect. Fluorescence-activated cell scan (FACS) assays found that RBD N501Y mutations are of higher binding affinity to ACE2 than the wild type. Surface plasmon resonance further indicated that N501Y mutation had a faster association rate and slower dissociation rate. Consistent with the kinetics study, atomic force microscopy-based single-molecule force microscopy quantify their strength on living cells, showing a higher binding probability and unbinding force for the mutation. Finally, Steered Molecular Dynamics (SMD) simulations on the dissociation of RBD-ACE2 complexes revealed that the N501Y introduced additional π-π and π-cation interaction for the higher force/interaction. Taken together, we suggested that the reinforced interaction from N501Y mutation in RBD should play an essential role in the higher transmission of COVID-19 variants. ### Competing Interest Statement The authors have declared no competing interest. * (COVID-19) : Coronavirus disease-19; (SARS-CoV-2) : Severe acute respiratory syndrome coronavirus-2; (RBD) : Receptor-binding domain (MERS-CoV) : Middle East respiratory syndrome coronavirus; (ACE2) : Angiotensin-converting enzyme 2; (SPR) : Surface Plasmon Resonance; (FACS) : Fluorescence-activated cell Scan; (AFM) : Atomic Force Microscopy; (SMFS) : Single-molecule force spectroscopy; (SMD) : Steered Molecular Dynamics.

Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations

GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Investigation of the Genetic Variation in ACE2 on the Structural Recognition by the Novel Coronavirus (Sars-Cov-2)

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants

Molecular Mechanism of the N501Y Mutation for Enhanced Binding between SARS-CoV-2’s Spike Protein and Human ACE2 Receptor

Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection

GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity

Potential use of the S-protein–Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects

Hydrophobic interaction determines docking affinity of SARS CoV 2 variants with antibodies

Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2

Global conserved RBD fraction of SARS-CoV-2 S-protein with T500S mutation in silico significantly blocks ACE2 and rejects viral spike

1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection